Laura F. Reddington

General Surgery

100 Grand St
New Britain, CT 06052

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1 publications

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

Journal: Clinical breast cancer

Published: September 13, 2013

Showing 1-1 of 1

Last Updated: 09/26/2026